What’s Next for Array Biopharma Inc (NASDAQ:ARRY) After Having More Shares Shorted?

September 16, 2018 - By Frank Plummer

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Investors sentiment decreased to 1.12 in Q2 2018. Its down 0.62, from 1.74 in 2018Q1. It is negative, as 33 investors sold Array BioPharma Inc. shares while 57 reduced holdings. 29 funds opened positions while 72 raised stakes. 190.66 million shares or 0.50% more from 189.71 million shares in 2018Q1 were reported.
10,200 were accumulated by Baxter Bros Incorporated. Castleark Management Limited Liability Co accumulated 331,435 shares or 0.17% of the stock. Kennedy Capital Mgmt reported 711,962 shares. Dekabank Deutsche Girozentrale has invested 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). 1.63M are owned by Ubs Asset Management Americas. Hanseatic Management Ser accumulated 0.35% or 24,214 shares. Clarivest Asset Lc invested in 0.05% or 180,757 shares. State Street holds 7.68 million shares or 0.01% of its portfolio. Boston Advsrs Ltd holds 0.02% in Array BioPharma Inc. (NASDAQ:ARRY) or 50,265 shares. Baker Bros L P has invested 0.71% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Mackay Shields Ltd Liability Co has invested 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Oppenheimer Asset Mngmt Incorporated reported 11,382 shares. Sei Invests owns 29,582 shares for 0% of their portfolio. Loring Wolcott & Coolidge Fiduciary Advsr Limited Liability Partnership Ma stated it has 6,550 shares or 0% of all its holdings. Farallon Mngmt Ltd Liability reported 0.48% stake.

Since March 21, 2018, it had 0 buys, and 14 insider sales for $9.02 million activity. $330,259 worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by VAN LUNSEN GIL J on Wednesday, May 16. On Wednesday, June 13 the insider Sandor Victor sold $420,450. $278,400 worth of Array BioPharma Inc. (NASDAQ:ARRY) shares were sold by Haddock Jason. On Wednesday, June 27 Robbins Andrew R sold $318,681 worth of Array BioPharma Inc. (NASDAQ:ARRY) or 17,964 shares. $3.31 million worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by Squarer Ron on Wednesday, June 27.

The stock of Array Biopharma Inc (NASDAQ:ARRY) registered an increase of 8.25% in short interest. ARRY’s total short interest was 14.63 million shares in September as published by FINRA. Its up 8.25% from 13.51 million shares, reported previously. With 2.24M shares average volume, it will take short sellers 7 days to cover their ARRY’s short positions.

The stock increased 0.07% or $0.01 during the last trading session, reaching $13.85. About 1.49 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 38.92% since September 16, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $2.94 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Among 4 analysts covering Array Biopharma (NASDAQ:ARRY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Array Biopharma had 5 analyst reports since May 10, 2018 according to SRatingsIntel. As per Tuesday, June 5, the company rating was maintained by Cowen & Co. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Piper Jaffray on Monday, June 25. The firm has “Outperform” rating by Wells Fargo given on Thursday, June 28. Cantor Fitzgerald maintained Array BioPharma Inc. (NASDAQ:ARRY) on Monday, June 25 with “Overweight” rating. The firm has “Buy” rating given on Thursday, May 10 by Cowen & Co.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Streetinsider.com, which released: “Array Biopharma (ARRY) Reports Publication of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) Phase 3 Overall …” on September 13, 2018. Seekingalpha.com‘s article titled: “Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug” and published on September 07, 2018 is yet another important article.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.